The 24th WIPO-CNIPA Awards for Chinese Outstanding Patented Inventions was held in Dalian in Northeast China on October 14. Hansoh Pharma's Ameile patent was proud to be honored with a China Patent Gold Award. The Awards were co-organized by the China National Intellectual Property Administration (CNIPA) and the World Intellectual Property Organization (WIPO), and receiving an award is the highest honor in the intellectual property industry in China. For Hansoh Pharma, it is the second time they have been recognized with such an honor.

 

Since 1989, the WIPO-CNIPA Awards for Chinese Outstanding Patented Inventions has been successfully held on 24 occasions focusing on core technologies in key industries and fields. Highlighted by the central role of manufacturing industry, the Awards helps to tackle bottlenecks in core technological research. They represent the highest standard of technology in the industry, and are an important manifestation of China's remarkable achievements in the area of intellectual property.

 

There are 29 inventions and utility model patents that were recognized at the recent Awards with a China Patent Gold Award. The invention patent "EGFR inhibitors and its preparations and applications" (Patent No.: ZL 201580045311.2), among the more than 2,400 patent entries being appraised, won a China Patent Gold Award, demonstrating Ameile's value to society and Hansoh Pharma's innovative strength.

 

Ameile (Almonertinib): Small Molecule Caters to Huge Demands

Since lung cancer has the highest incidence among the different types of cancer in China, the clinical demand for third-generation drugs targeting epidermal growth factor receptor (EGFR) is urgent. The researchers from Hansoh Pharma designed the new drug molecule Almonertinib through innovation and R&D efforts, filling a void in China's third-generation EGFR inhibitors to overcome the monopoly over imported drugs and providing world-leading treatment regimens for patients with non-small cell lung cancer (NSCLC).

 

As Asia's first and the second global third-generation EGFR inhibitor, Ameile is used in the first-line treatment of EGFR-mutated NSCLC and two approved indications have been included in the National Reimbursement Drug List (NRDL), greatly reducing the burden of patients and society due to lung cancer. 

 

Intellectual Property: High-Value Patent Safeguards Full-Cycle Operations

Hansoh Pharma attaches great importance to intellectual property management, and its intellectual property management system was certified by the national standard in 2015. Its subsidiary, Jiangsu Hansoh Pharma, was recognized as a National Intellectual Property Model Enterprise for many consecutive years.

 

Hansoh Pharma deeply promotes development and management regulations for high-value patents, and establishes a complete development cycle for each innovative drug and intellectual property globally. Combined with the results of innovative products at different stages of R&D, the patent administrative department determines a series of patents for various types of technology such as drug compounds, pharmaceutical salt/crystal forms, drug products and preparation processes, and new medical applications, and applies for diverse protection aimed at core patents in countries overseas. Currently, the Ameile patent has entered 13 nations and regions worldwide, and has been authorized in nations and regions such as China, the United States, Europe, and Japan.

 

Thus far, Hansoh Pharma has won a total of two China Patent Gold Awards, one Silver Award, and six Excellence Awards. The Ameile's China Patent Gold Award states that the CNIPA and WIPO highly recognize Hansoh Pharma's standards in patent technology and innovative prowess. Hansoh Pharma will continue to make scientific breakthroughs and leading technological innovations. It will also build a world-class leading drug manufacturing paradigm, making contributions to self-reliance and strength in China's high standards of science and technology and economic and social development.